Q62371
Gene name |
Ddr2 (Ntrkr3, Tkt, Tyro10) |
Protein name |
Discoidin domain-containing receptor 2 |
Names |
Discoidin domain receptor 2 , EC 2.7.10.1 , CD167 antigen-like family member B , Neurotrophic tyrosine kinase, receptor-related 3 , Receptor protein-tyrosine kinase TKT , Tyrosine-protein kinase TYRO10 , CD antigen CD167b |
Species |
Mus musculus (Mouse) |
KEGG Pathway |
mmu:18214 |
EC number |
2.7.10.-: Protein-tyrosine kinases |
Protein Class |
|

Descriptions
Autoinhibitory domains (AIDs)
Target domain |
563-848 (Protein kinase domain) |
Relief mechanism |
PTM |
Assay |
|
Accessory elements
No accessory elements
References
- Yeon JH et al. (2016) "Systems-wide Identification of cis-Regulatory Elements in Proteins", Cell systems, 2, 89-100
- Sammon D et al. (2020) "Two-step release of kinase autoinhibition in discoidin domain receptor 1", Proceedings of the National Academy of Sciences of the United States of America, 117, 22051-22060
- Fu HL et al. (2014) "Glycosylation at Asn211 regulates the activation state of the discoidin domain receptor 1 (DDR1)", The Journal of biological chemistry, 289, 9275-87
Autoinhibited structure

Activated structure

1 structures for Q62371
Entry ID | Method | Resolution | Chain | Position | Source |
---|---|---|---|---|---|
AF-Q62371-F1 | Predicted | AlphaFoldDB |
44 variants for Q62371
Variant ID(s) | Position | Change | Description | Diseaes Association | Provenance |
---|---|---|---|---|---|
rs3388512702 | 16 | L>F | No | EVA | |
rs3388510744 | 24 | Q>H | No | EVA | |
rs3390938223 | 68 | G>* | No | EVA | |
rs3388514700 | 72 | W>C | No | EVA | |
rs47694293 | 74 | P>L | No | EVA | |
rs31474649 | 87 | L>M | No | EVA | |
rs3388516006 | 91 | L>* | No | EVA | |
rs3388509255 | 102 | T>A | No | EVA | |
rs3388515437 | 105 | R>G | No | EVA | |
rs3388515182 | 113 | E>V | No | EVA | |
rs3388509236 | 114 | F>S | No | EVA | |
rs3388515448 | 171 | D>E | No | EVA | |
rs3388515632 | 176 | V>M | No | EVA | |
rs3388511303 | 188 | L>V | No | EVA | |
rs3388515635 | 190 | G>D | No | EVA | |
rs3388514286 | 202 | F>L | No | EVA | |
rs3390965723 | 212 | L>Q | No | EVA | |
rs3388515453 | 229 | L>P | No | EVA | |
rs3388514701 | 234 | D>E | No | EVA | |
rs3388514706 | 263 | S>G | No | EVA | |
rs232897194 | 264 | A>T | No | EVA | |
rs3388515639 | 293 | A>D | No | EVA | |
rs3388511299 | 296 | V>M | No | EVA | |
rs3388514333 | 342 | M>T | No | EVA | |
rs3388511139 | 358 | M>T | No | EVA | |
rs3388513471 | 435 | R>M | No | EVA | |
rs3388517430 | 440 | E>D | No | EVA | |
rs3388512264 | 440 | E>Q | No | EVA | |
rs3388514731 | 474 | I>L | No | EVA | |
rs3388517458 | 478 | R>L | No | EVA | |
rs242021756 | 510 | A>V | No | EVA | |
rs3391003431 | 576 | E>G | No | EVA | |
rs3388511089 | 582 | V>* | No | EVA | |
rs3388517429 | 585 | M>V | No | EVA | |
rs3388515418 | 588 | F>L | No | EVA | |
rs31474355 | 590 | D>G | No | EVA | |
rs3388515414 | 609 | M>I | No | EVA | |
rs3388515597 | 622 | F>S | No | EVA | |
rs3388513531 | 669 | H>P | No | EVA | |
rs3388512266 | 705 | F>L | No | EVA | |
rs3388516024 | 728 | F>L | No | EVA | |
rs3388512804 | 827 | M>L | No | EVA | |
rs3388515583 | 834 | E>K | No | EVA | |
rs3388510672 | 845 | H>Q | No | EVA |
1 associated diseases with Q62371
Without disease ID
7 regional properties for Q62371
Type | Name | Position | InterPro Accession |
---|---|---|---|
domain | Coagulation factor 5/8 C-terminal domain | 29 - 185 | IPR000421 |
domain | Protein kinase domain | 563 - 848 | IPR000719 |
domain | Serine-threonine/tyrosine-protein kinase, catalytic domain | 564 - 845 | IPR001245 |
conserved_site | Tyrosine-protein kinase, receptor class II, conserved site | 733 - 741 | IPR002011 |
active_site | Tyrosine-protein kinase, active site | 705 - 717 | IPR008266 |
domain | Tyrosine-protein kinase, catalytic domain | 563 - 848 | IPR020635 |
domain | Discoidin domain-containing receptor 1/2, DS-like domain | 190 - 366 | IPR048525 |
Functions
Description | ||
---|---|---|
EC Number | 2.7.10.- | Protein-tyrosine kinases |
Subcellular Localization |
|
|
PANTHER Family | ||
PANTHER Subfamily | ||
PANTHER Protein Class | ||
PANTHER Pathway Category | No pathway information available |
3 GO annotations of cellular component
Name | Definition |
---|---|
actin cytoskeleton | The part of the cytoskeleton (the internal framework of a cell) composed of actin and associated proteins. Includes actin cytoskeleton-associated complexes. |
apical plasma membrane | The region of the plasma membrane located at the apical end of the cell. |
receptor complex | Any protein complex that undergoes combination with a hormone, neurotransmitter, drug or intracellular messenger to initiate a change in cell function. |
4 GO annotations of molecular function
Name | Definition |
---|---|
ATP binding | Binding to ATP, adenosine 5'-triphosphate, a universally important coenzyme and enzyme regulator. |
collagen binding | Binding to collagen, a group of fibrous proteins of very high tensile strength that form the main component of connective tissue in animals. Collagen is highly enriched in glycine (some regions are 33% glycine) and proline, occurring predominantly as 3-hydroxyproline (about 20%). |
protein tyrosine kinase collagen receptor activity | Combining with collagen and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity by catalysis of the reaction |
transmembrane receptor protein tyrosine kinase activity | Combining with a signal and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity by catalysis of the reaction |
32 GO annotations of biological process
Name | Definition |
---|---|
biomineral tissue development | Formation of hard tissues that consist mainly of inorganic compounds, and also contain a small amounts of organic matrices that are believed to play important roles in their formation. |
cellular response to angiotensin | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an angiotensin stimulus. Angiotensin is any of three physiologically active peptides (angiotensin II, III, or IV) processed from angiotensinogen. |
cellular response to hypoxia | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating lowered oxygen tension. Hypoxia, defined as a decline in O2 levels below normoxic levels of 20.8 - 20.95%, results in metabolic adaptation at both the cellular and organismal level. |
cellular response to transforming growth factor beta stimulus | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a transforming growth factor beta stimulus. |
chondrocyte proliferation | The multiplication or reproduction of chondrocytes by cell division, resulting in the expansion of their population. A chondrocyte is a polymorphic cell that forms cartilage. |
collagen fibril organization | Any process that determines the size and arrangement of collagen fibrils within an extracellular matrix. |
collagen-activated tyrosine kinase receptor signaling pathway | The series of molecular signals initiated by collagen binding to its receptor on the surface of a target cell where the receptor possesses tyrosine kinase activity, and ending with the regulation of a downstream cellular process, e.g. transcription. |
endochondral bone growth | The increase in size or mass of an endochondral bone that contributes to the shaping of the bone. |
negative regulation of apoptotic process | Any process that stops, prevents, or reduces the frequency, rate or extent of cell death by apoptotic process. |
negative regulation of hydrogen peroxide-mediated programmed cell death | Any process that stops, prevents or reduces the frequency, rate or extent of hydrogen peroxide-mediated programmed cell death. |
ossification | The formation of bone or of a bony substance, or the conversion of fibrous tissue or of cartilage into bone or a bony substance. |
peptidyl-tyrosine phosphorylation | The phosphorylation of peptidyl-tyrosine to form peptidyl-O4'-phospho-L-tyrosine. |
positive regulation of cell population proliferation | Any process that activates or increases the rate or extent of cell proliferation. |
positive regulation of collagen biosynthetic process | Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of collagen, any of a group of fibrous proteins of very high tensile strength that form the main component of connective tissue in animals. |
positive regulation of DNA-binding transcription factor activity | Any process that activates or increases the frequency, rate or extent of activity of a transcription factor, any factor involved in the initiation or regulation of transcription. |
positive regulation of ERK1 and ERK2 cascade | Any process that activates or increases the frequency, rate or extent of signal transduction mediated by the ERK1 and ERK2 cascade. |
positive regulation of extracellular matrix disassembly | Any process that increases the rate, frequency or extent of extracellular matrix disassembly. Extracellular matrix disassembly is a process that results in the breakdown of the extracellular matrix. |
positive regulation of fibroblast migration | Any process that increases the rate, frequency or extent of fibroblast cell migration. Fibroblast cell migration is accomplished by extension and retraction of a pseudopodium. |
positive regulation of fibroblast proliferation | Any process that activates or increases the frequency, rate or extent of multiplication or reproduction of fibroblast cells. |
positive regulation of G1/S transition of mitotic cell cycle | Any signalling pathway that increases or activates a cell cycle cyclin-dependent protein kinase to modulate the switch from G1 phase to S phase of the mitotic cell cycle. |
positive regulation of hepatic stellate cell activation | Any process that activates or increases the frequency, rate or extent of hepatic stellate cell activation. |
positive regulation of hepatic stellate cell proliferation | Any process that activates or increases the frequency, rate or extent of hepatic stellate cell proliferation. |
positive regulation of neuron projection development | Any process that increases the rate, frequency or extent of neuron projection development. Neuron projection development is the process whose specific outcome is the progression of a neuron projection over time, from its formation to the mature structure. A neuron projection is any process extending from a neural cell, such as axons or dendrites (collectively called neurites). |
positive regulation of osteoblast differentiation | Any process that activates or increases the frequency, rate or extent of osteoblast differentiation. |
positive regulation of protein kinase activity | Any process that activates or increases the frequency, rate or extent of protein kinase activity. |
positive regulation of vascular associated smooth muscle cell migration | Any process that activates or increases the frequency, rate or extent of vascular associated smooth muscle cell migration. |
positive regulation of vascular associated smooth muscle cell proliferation | Any process that activates or increases the frequency, rate or extent of vascular smooth muscle cell proliferation. |
positive regulation of wound healing | Any process that increases the rate, frequency, or extent of the series of events that restore integrity to a damaged tissue, following an injury. |
regulation of bone mineralization | Any process that modulates the frequency, rate or extent of bone mineralization. |
regulation of tissue remodeling | Any process that modulates the frequency, rate, or extent of tissue remodeling. |
response to muscle stretch | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a myofibril being extended beyond its slack length. |
transmembrane receptor protein tyrosine kinase signaling pathway | The series of molecular signals initiated by an extracellular ligand binding to a receptor on the surface of the target cell where the receptor possesses tyrosine kinase activity, and ending with the regulation of a downstream cellular process, e.g. transcription. |
47 homologous proteins in AiPD
UniProt AC | Gene Name | Protein Name | Species | Evidence Code |
---|---|---|---|---|
Q5F3X2 | DDR1 | receptor protein-tyrosine kinase | Gallus gallus (Chicken) | SS |
Q7YR43 | DDR1 | Epithelial discoidin domain-containing receptor 1 | Pan troglodytes (Chimpanzee) | SS |
Q08345 | DDR1 | Epithelial discoidin domain-containing receptor 1 | Homo sapiens (Human) | EV |
Q16832 | DDR2 | Discoidin domain-containing receptor 2 | Homo sapiens (Human) | SS |
P35546 | Ret | Proto-oncogene tyrosine-protein kinase receptor Ret | Mus musculus (Mouse) | SS |
Q61006 | Musk | Muscle, skeletal receptor tyrosine-protein kinase | Mus musculus (Mouse) | SS |
Q9Z138 | Ror2 | Tyrosine-protein kinase transmembrane receptor ROR2 | Mus musculus (Mouse) | SS |
Q9Z139 | Ror1 | Inactive tyrosine-protein kinase transmembrane receptor ROR1 | Mus musculus (Mouse) | PR |
Q03146 | Ddr1 | Epithelial discoidin domain-containing receptor 1 | Mus musculus (Mouse) | SS |
P15209 | Ntrk2 | BDNF/NT-3 growth factors receptor | Mus musculus (Mouse) | SS |
Q3UFB7 | Ntrk1 | High affinity nerve growth factor receptor | Mus musculus (Mouse) | SS |
Q6VNS1 | Ntrk3 | NT-3 growth factor receptor | Mus musculus (Mouse) | SS |
P35917 | Flt4 | Vascular endothelial growth factor receptor 3 | Mus musculus (Mouse) | SS |
P35969 | Flt1 | Vascular endothelial growth factor receptor 1 | Mus musculus (Mouse) | SS |
P35918 | Kdr | Vascular endothelial growth factor receptor 2 | Mus musculus (Mouse) | PR |
Q03145 | Epha2 | Ephrin type-A receptor 2 | Mus musculus (Mouse) | PR |
Q60750 | Epha1 | Ephrin type-A receptor 1 | Mus musculus (Mouse) | SS |
P54761 | Ephb4 | Ephrin type-B receptor 4 | Mus musculus (Mouse) | PR |
Q60629 | Epha5 | Ephrin type-A receptor 5 | Mus musculus (Mouse) | SS |
P97793 | Alk | ALK tyrosine kinase receptor | Mus musculus (Mouse) | SS |
Q9WTL4 | Insrr | Insulin receptor-related protein | Mus musculus (Mouse) | SS |
Q60751 | Igf1r | Insulin-like growth factor 1 receptor | Mus musculus (Mouse) | SS |
P15208 | Insr | Insulin receptor | Mus musculus (Mouse) | SS |
P16092 | Fgfr1 | Fibroblast growth factor receptor 1 | Mus musculus (Mouse) | SS |
P21803 | Fgfr2 | Fibroblast growth factor receptor 2 | Mus musculus (Mouse) | SS |
Q03142 | Fgfr4 | Fibroblast growth factor receptor 4 | Mus musculus (Mouse) | PR |
Q60805 | Mertk | Tyrosine-protein kinase Mer | Mus musculus (Mouse) | SS |
Q62190 | Mst1r | Macrophage-stimulating protein receptor | Mus musculus (Mouse) | SS |
Q00993 | Axl | Tyrosine-protein kinase receptor UFO | Mus musculus (Mouse) | PR |
P55144 | Tyro3 | Tyrosine-protein kinase receptor TYRO3 | Mus musculus (Mouse) | SS |
P70424 | Erbb2 | Receptor tyrosine-protein kinase erbB-2 | Mus musculus (Mouse) | SS |
Q61527 | Erbb4 | Receptor tyrosine-protein kinase erbB-4 | Mus musculus (Mouse) | SS |
Q61526 | Erbb3 | Receptor tyrosine-protein kinase erbB-3 | Mus musculus (Mouse) | SS |
Q01279 | Egfr | Epidermal growth factor receptor | Mus musculus (Mouse) | SS |
Q01887 | Ryk | Tyrosine-protein kinase RYK | Mus musculus (Mouse) | PR |
Q02858 | Tek | Angiopoietin-1 receptor | Mus musculus (Mouse) | SS |
Q06806 | Tie1 | Tyrosine-protein kinase receptor Tie-1 | Mus musculus (Mouse) | SS |
P05532 | Kit | Mast/stem cell growth factor receptor Kit | Mus musculus (Mouse) | PR |
P05622 | Pdgfrb | Platelet-derived growth factor receptor beta | Mus musculus (Mouse) | SS |
P09581 | Csf1r | Macrophage colony-stimulating factor 1 receptor | Mus musculus (Mouse) | SS |
P26618 | Pdgfra | Platelet-derived growth factor receptor alpha | Mus musculus (Mouse) | SS |
Q00342 | Flt3 | Receptor-type tyrosine-protein kinase FLT3 | Mus musculus (Mouse) | SS |
Q61851 | Fgfr3 | Fibroblast growth factor receptor 3 | Mus musculus (Mouse) | PR |
P16056 | Met | Hepatocyte growth factor receptor | Mus musculus (Mouse) | PR |
Q63474 | Ddr1 | Epithelial discoidin domain-containing receptor 1 | Rattus norvegicus (Rat) | SS |
Q95ZV7 | ddr-2 | Discoidin domain-containing receptor tyrosine kinase B | Caenorhabditis elegans | PR |
E7F3X9 | ddr1 | receptor protein-tyrosine kinase | Danio rerio (Zebrafish) (Brachydanio rerio) | SS |
10 | 20 | 30 | 40 | 50 | 60 |
MIPIPRMPLV | LLLLLLILGS | AKAQVNPAIC | RYPLGMSGGH | IPDEDITASS | QWSESTAAKY |
70 | 80 | 90 | 100 | 110 | 120 |
GRLDSEEGDG | AWCPEIPVQP | DDLKEFLQID | LRTLHFITLV | GTQGRHAGGH | GIEFAPMYKI |
130 | 140 | 150 | 160 | 170 | 180 |
NYSRDGSRWI | SWRNRHGKQV | LDGNSNPYDV | FLKDLEPPIV | ARFVRLIPVT | DHSMNVCMRV |
190 | 200 | 210 | 220 | 230 | 240 |
ELYGCVWLDG | LVSYNAPAGQ | QFVLPGGSII | YLNDSVYDGA | VGYSMTEGLG | QLTDGVSGLD |
250 | 260 | 270 | 280 | 290 | 300 |
DFTQTHEYHV | WPGYDYVGWR | NESATNGFIE | IMFEFDRIRN | FTTMKVHCNN | MFAKGVKIFK |
310 | 320 | 330 | 340 | 350 | 360 |
EVQCYFRSEA | SEWEPTAVYF | PLVLDDVNPS | ARFVTVPLHH | RMASAIKCQY | HFADTWMMFS |
370 | 380 | 390 | 400 | 410 | 420 |
EITFQSDAAM | YNNSGALPTS | PMAPTTYDPM | LKVDDSNTRI | LIGCLVAIIF | ILLAIIVIIL |
430 | 440 | 450 | 460 | 470 | 480 |
WRQFWQKMLE | KASRRMLDDE | MTVSLSLPSE | SSMFNNNRSS | SPSEQESNST | YDRIFPLRPD |
490 | 500 | 510 | 520 | 530 | 540 |
YQEPSRLIRK | LPEFAPGEEE | SGCSGVVKPA | QPNGPEGVPH | YAEADIVNLQ | GVTGGNTYCV |
550 | 560 | 570 | 580 | 590 | 600 |
PAVTMDLLSG | KDVAVEEFPR | KLLAFKEKLG | EGQFGEVHLC | EVEGMEKFKD | KDFALDVSAN |
610 | 620 | 630 | 640 | 650 | 660 |
QPVLVAVKML | RADANKNARN | DFLKEIKIMS | RLKDPNIIRL | LAVCITEDPL | CMITEYMENG |
670 | 680 | 690 | 700 | 710 | 720 |
DLNQFLSRHE | PLSSCSSDAT | VSYANLKFMA | TQIASGMKYL | SSLNFVHRDL | ATRNCLVGKN |
730 | 740 | 750 | 760 | 770 | 780 |
YTIKIADFGM | SRNLYSGDYY | RIQGRAVLPI | RWMSWESILL | GKFTTASDVW | AFGVTLWETF |
790 | 800 | 810 | 820 | 830 | 840 |
TFCQEQPYSQ | LSDEQVIENT | GEFFRDQGRQ | IYLPQPALCP | DSVYKLMLSC | WRRETKHRPS |
850 | |||||
FQEIHLLLLQ | QGAE |